Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

OTCQB:CYTOF - Post by User

Altamira Therapeutics Ltd

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon May 23, 2024 9:06am

66 Views

Post# 36053656

CYTO.....early a.m runner up on NR this a.m...but

Go ahead and chase this.......you're all going to get screwed

Here is why......

https://www.sec.gov/Archives/edgar/data/1601936/000121390024033817/ea0203993-424b4_altamira.htm

<< Previous

Bullboard Posts

Next >>

How Canadian investors can benefit from flow-through shares